LEVEL 4 N04BC05

Δραστικές

Φάρμακα

  • DRUGBANK - Pramipexole
  • indication:

    For the treatment of signs and symptoms of idiopathic Parkinson's disease

  • pharmacology:

  • mechanism:

    The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.

  • toxicity:

  • absorprion:

    Rapid. Absolute bioavailability is greater than 90%, indicating that pramipexole is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of absorption.

  • halflife:

    8 hours

  • roouteelimination:

    Urinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. Nonrenal routes may contribute to a small extent to pramipexole elimination, although no metabolites have been identified in plasma or urine.

  • volumedistribution:

    * 500 L

  • clearance:

    * renal cl=400 mL/min